Immune checkpoint inhibitors can enhance the antitumor activity of the immune 
system by mainly promoting CD8+ T lymphocyte immune function. However, they can 
also induce immune-related adverse events, especially skin toxicity. Some 
studies found that patients with autoimmune or inflammatory disease are 
susceptible to immune checkpoint inhibitors and were associated with a 
significantly increased risk of immune-related adverse events. In our present 
report, we described a newly diagnosed non-small-cell lung cancer patient who 
suffered from focal vitiligo for approximately ten years and was treated with 
the anti-programmed cell death-1 receptor antibody camrelizumab (SHR-1210), 
which accelerated the aggravation of depigmentation of the skin over the whole 
body in just half a year.